Introduction
Diabetes mellitus is a c ommon and growing health problem worldwide. In Singapore, the prevalenc e of diabetes mellitus among adults has risen from 1 ·9 % in 1 9 7 5 and 4 ·7 % in 1 9 8 4 to 8 ·6 % in 1 9 9 2 1 . In the 1 9 9 8
National Health Survey ( NHS) , the c rude prevalenc e of diabetes was 8 ·5 % in males and 9 ·6 % in females 2 . Among the ethnic groups, the prevalenc e was highest among the Indians ( 1 5 ·8 %) , followed by the Malays ( 1 1 ·3 %) and Chinese ( 8 ·0 %) . It was also noted that type 2 diabetes mellitus is inc reasing in the youth and in c hildren. The survey found that 6 2 ·1 % of Singapore residents who had diabetes mellitus ( through sc reening) had not been previously diagnosed.
Diabetes mellitus is generally managed by the Ministry of Health outpatient polyc linic s, with almost 1 -in-1 0 visits ( approximately 3 5 0 ,0 0 0 ) per year attributable to diabetes mellitus 3 . In 1 9 9 8 , about 2 4 0 ,0 0 0 bed-days, ac c ounting for 8 % of the total, were utilised for diabetes mellitus management, with an average length of stay per episode of 8 ·8 days. Diabetes mellitus-related deaths are the sixth c ommonest c ause the death in Singapore, c ontributing to 9 ·3 % of mortality statistic s 4 .
Diabetes mellitus is a c hronic and c omplex disease, requiring c ontinued life-long management aimed at reduc ing the high morbidity and premature mortality c aused by c hronic c omplic ations assoc iated with the disease. Many people with diabetes mellitus rec eive suboptimal c are. In a rec ent DiabCare Asia Study c onduc ted to assess the status of diabetes mellitus c ontrol and c hronic c omplic ations, about 5 0 % of almost 1 7 0 0 Singapore patients surveyed at hospital and government outpatient c linic s had glyc ated haemoglobin levels in the sub-optimal or unac c eptable levels 5 .
Screening of Asymptomatic Individuals
The 1 9 9 8 National Health Survey showed that 6 2 ·1 % of Singaporeans detec ted to have diabetes were previously unaware of the diagnosis. This is c onsistent with reports that type 2 diabetes mellitus generally manifests 4 -7 years prior to c linic al diagnosis 6 . Fingerpric k c apillary blood gluc ose measured by a portable gluc ometer is not c onsidered to have suffic ient ac c urac y for initial diagnosis of diabetes, but c an be used for sc reening purposes. Individuals sc reened to have fasting c apillary blood gluc ose > 6 ·0 mmol/L or c asual c apillary blood gluc ose > = 7 ·8 mmol/L using a gluc ometer should have venous blood taken and sent for estimation of venous plasma gluc ose by a standardised laboratory based determination.
The loc al rec ommended guidelines for the sc reening of asymptomatic individuals for diabetes mellitus are:
• All individuals aged 4 0 and above, at 3 yearly intervals.
• 
Diagnosis
In a patient with typic al symptoms of hyperglyc aemia, diabetes mellitus c an be diagnosed on any one of the following c riteria:
• 2 -hour plasma gluc ose following an oral gluc ose toleranc e test ( OGTT) > = 1 1 ·1 mmol/L Venous blood should be c ollec ted in appropriate tubes for plasma gluc ose determination by a standardised laboratory based method. When typic al symptoms of hyperglyc aemia are absent, a sec ond c onfirmatory test on another day is required. Fasting plasma gluc ose remains the diagnostic test of c hoic e for establishing and doc umenting the onset of diabetes.
Integrated Management of Diabetes
Diabetes c are should be struc tured and organised around purpose-built Diabetes Centres, where an interdisc iplinary team approac h to the management of diabetes c an be effec tively organised with minimal inc onvenienc e to the patient. The management team should inc lude the primary c are doc tor, diabetes educ ators with direc t ac c ess to diabetes spec ialists and other support professionals, and health-c are providers suc h as c ardiologist, ophthalmologists, neurologists, nephrologists, podiatrists, pharmac ists and soc ial workers.
Glycaemic Control: Self-Monitoring of Blood Glucose
Abbott/MediSense Laboratories, YSI, Bayer Corporation, Boehringer Mannheim, The Roc he Group, Home Diagnostic s, Inc ., LifeSc an Inc ., Inverness Medic al, and Kyoto Daiic hi produc e the more popular c ommerc ial blood-gluc ose meters. The measurement requires a 3 -to 1 0 -µL drop of blood and usually takes < 1 min. Although all meters take a whole-blood sample to c alc ulate blood gluc ose, some of the newer meters and/or test strips have been c alibrated to provide the result as a plasma equivalent. Plasma-c alibrated meters and/or test strips make it easier for c omparison between gluc ometer and laboratory reported results. A plasma-c alibrated meter will report a reading ~1 2 % higher than a whole blood c alibrated meter 8 .
The prec ision of suc h devic es is highly operator-dependent and this requires metic ulous adherenc e to the manufac turer's instruc tions. Besides poor tec hnique and inadequate amount of blood sample, other c ommon errors are due to defec tive or expired test strips, inc orrec t c alibration and instrument failure. Initial training for the use of blood gluc ometers should be provided by qualified staff rather than having the patient read through the manufac turer's manual. The importanc e of meter c alibration should be highlighted. Annual reviews appear to be nec essary to verify users' c ompetenc y, provide an update of the advanc es of home gluc ose devic es, and evaluate the c orrelation between c apillary gluc ose levels on the gluc ometer with a simultaneous venous sample analysed by a c entral laboratory. Calibration c hec ks of meters should also be c onduc ted with standard solutions ac c ording to the manufac turer's rec ommendations.
Self-monitoring of c apillary blood gluc ose ( SMBG) by patients should be an integral part of diabetes self -c are.
Charting of day-to-day trend should form the basis of finetuning the appropriate therapy and to assess the effic ac y of treatment 9 .
A suggested regime for home monitoring is as follows:
• For patients with type 1 diabetes and most insulintreated type 2 patients, a frequenc y of one to two days per week is rec ommended.
• For non insulin-treated patients, SMBG may be performed less frequently but it should be done suffic iently to fac ilitate reac hing gluc ose target levels.
• For patients with unstable metabolic c ontrol, c hanges in daily routine, alterations of treatment regimens or inter-c urrent illness, the frequenc y of SBGM should be inc reased.
Glycaemic Control: Glycated H aemoglobin Testing
In the 1 9 9 0 s, in of their patients. Unlike the rapid fluc tuation of gluc ose in blood, the measurement of glyc ated haemoglobin quantifies average glyc aemia over the prec eding 2 -3 months. This tool c omplements and provides a more stable index c ompared to blood gluc ose testing, whic h indic ates day-to-day glyc aemic exc ursions.
The term "glyc ated haemoglobin" refers c ollec tively to a sequenc e of stable adduc ts, whic h are formed between haemoglobin and sugars, where glyc ated haemoglobin A1 c ( HbA1 c ) is the most important indic ator of the degree of severity of diabetes. The frac tion of HbA1 c in healthy adults is ~5 %, but it c an inc rease two-to threefold in patients with diabetes mellitus. The availability of glyc ated haemoglobin ( HbA1 c ) has revolutionised diabetes management. Ion exc hange, affinity c hromatography, and elec trophoresis are the major analytic al methods for HbA1 c determination. Tec hnic al issues of assay standardisation no longer hamper and limit the c linic al applic ation of glyc ated haemoglobin. In 1 9 9 6 , the US National Glyc ohemoglobin Standardization Program ( NGSP) Steering Committee implemented a programme that would enable laboratories to report DCCT-trac eable standarised glyc ohaemoglobin results.
As many different types of glyc ated haemoglobin assay methods are available in the routine c linic al laboratory, physic ians ordering the test should be aware of the assay method used, the glyc ated c omponents measured ( HbA1 , or HbA1 c ) , the non-diabetic referenc e interval, and potential assay interferenc es.
The following sc hedule is rec ommended for glyc ated haemoglobin testing 1 2 :
• 3 -4 monthly in patients with unstable glyc aemic c ontrol, failure to meet treatment goals, rec ent adjustment in therapy, or intensive insulin therapy.
• 6 -monthly in patients who have stable glyc aemic c ontrol and who are meeting treatment goals. 
Management of Concomitant Conditions Diabetic Dyslipidaemia
The rec ently announc ed Adult Treatment Panel ( ATP III) of the National Cholesterol Educ ation Program ( NCEP) has put an inc reased emphasis on the management of lipids in persons with diabetes. Those with multiple metabolic risk fac tors ( the metabolic syndrome) are identified as c andidates for intensified therapeutic lifestyle c hanges. The status of persons with type 2 diabetes has been rec ognised to be equivalent to that of having established c oronary heart disease ( CHD) . The primary target of therapy is the identific ation of low-density lipoprotein c holesterol ( LDL-C) , for whic h the goal for persons with diabetes is < 2 ·6 mmol/L ( 1 0 0 mg/dL) , irrespec tive of whether or not there is doc umented CHD1 3 .
Most Singaporean diabetic s have some degree of dyslipidaemia/ hyperc holesterolaemia. Consequently, atherosc lerotic heart disease is a substantial risk to the diabetic population and ac c ounts for over 7 5 % of hospitalisations for diabetic c omplic ations. People with diabetes are far more susc eptible to c oronary heart disease ( CHD) than the general population and suggests that longterm, aggressive c ontrol of lipid levels is as c ritic al as that of glyc aemic c ontrol. Aggressive lipid lowering, although a desirable goal, does not yet appear to be standard prac tic e.
Microalbuminuria
Mic roalbuminuria is an important risk fac tor for the development of progressive diabetic nephropathy. It is usually detec ted in 3 0 % of patients with type 1 diabetes between 5 -1 5 years after diagnosis. In type 2 diabetes, there is already a high prevalenc e of dipstic k positive albuminuria, at the time of diagnosis 1 4 . Early detec tion of mic roalbuminuria allows identific ation of selec ted patients who would benefit from aggressive intervention to forestall the onset of overt renal disease. Mic roalbuminuria is defined as either an albumin c onc entration of 2 0 -2 0 0 mg/ L or an albumin: c reatinine ratio of > 3 ·5 ( women) and > 2 ·5 g/mmol ( men) on first void morning urine. Albumin exc retion rates ( AER) of 2 0 -2 0 0 ug/min or 3 0 -3 0 0 mg/ day are also c ommonly used to define mic roalbuminuria.
Performance Parameter Recommended Frequency
Home glucose monitoring (fasting) 1 -4 times a week Glycated haemoglobin (HbA1c) 2 -4 times a year Urine albumin: creatinine ratio 4 times a year Lipid profile 4 times a year Serum creatinine 4 times a year T T T T Table 2  able 2  able 2  able 2  able 2 Summary Table 2 summarises the suggested bioc hemic al surveillanc e parameters in the management of diabetes mellitus. Diabetes is a c hronic illness with numerous serious c omplic ations resulting in signific ant morbidity and mortality. Addressing issues of medic al effec tiveness of treatment and c ontinuous improvement of the quality of c are of patients with diabetes have been shown to have signific ant positive impac t on the patient, the c ommunity and health servic e provider.
